Suppr超能文献

结直肠癌肝转移灶射频消融的肿瘤学结局及预测因素

Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases.

作者信息

Wang Chuan-Zhuo, Yan Guang-Xin, Xin He, Liu Zhao-Yu

机构信息

Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.

出版信息

World J Gastrointest Oncol. 2020 Sep 15;12(9):1044-1055. doi: 10.4251/wjgo.v12.i9.1044.

Abstract

BACKGROUND

Surgical resection is considered the standard treatment option for long-term survival in colorectal cancer liver metastasis (CRLM) patients, but only a small number of patients are suitable for resection following diagnosis. Radiofrequency ablation (RFA) is an accepted alternative therapy for CRLM patients who are not suitable for resection. However, the relatively high rate of local tumor progression (LTP) is an obstacle to the more widespread use of RFA.

AIM

To determine the oncological outcomes and predictors of RFA in CRLM patients.

METHODS

A retrospective analyze was performed on the clinical data of 85 consecutive CRLM patients with a combined total of 138 liver metastases, who had received percutaneous RFA treatment at our institution from January 2013 to December 2018. Contrast-enhanced computed tomography was performed the first month after RFA to assess the technique effectiveness of the RFA and to serve as a baseline for subsequent evaluations. The Kaplan-Meier method was used to calculate overall survival (OS) and LTP-free survival (LTPFS). The log-rank test and Cox regression model were used for univariate and multivariate analyses to determine the predictors of the oncological outcomes.

RESULTS

There were no RFA procedure-related deaths, and the technique effectiveness of the treatment was 89.1% (123/138). The median follow-up time was 30 mo. The LTP rate was 32.6% (45/138), and the median OS was 36 mo. The 1-, 3-, and 5-year OS rates were 90.6%, 45.6%, and 22.9%, respectively. Univariate analysis revealed that tumor size and ablative margin were the factors influencing LTPFS, while extrahepatic disease (EHD), tumor number, and tumor size were the factors influencing OS. Multivariate analysis showed that tumor size larger than 3 cm and ablative margin of 5 mm or smaller were the independent predictors of shorter LTPFS, while tumor number greater than 1, size larger than 3 cm, and presence of EHD were the independent predictors of shorter OS.

CONCLUSION

RFA is a safe and effective treatment method for CRLM. Tumor size and ablative margin are the important factors affecting LTPFS. Tumor number, tumor size, and EHD are also critical factors for OS.

摘要

背景

手术切除被认为是结直肠癌肝转移(CRLM)患者长期生存的标准治疗选择,但只有少数患者在诊断后适合切除。射频消融(RFA)是不适合切除的CRLM患者可接受的替代治疗方法。然而,相对较高的局部肿瘤进展(LTP)率是RFA更广泛应用的障碍。

目的

确定CRLM患者RFA的肿瘤学结局和预测因素。

方法

对2013年1月至2018年12月在本机构接受经皮RFA治疗的85例连续CRLM患者的临床资料进行回顾性分析,这些患者共有138处肝转移灶。RFA术后第1个月进行对比增强计算机断层扫描,以评估RFA的技术有效性,并作为后续评估的基线。采用Kaplan-Meier法计算总生存期(OS)和无局部肿瘤进展生存期(LTPFS)。采用对数秩检验和Cox回归模型进行单因素和多因素分析,以确定肿瘤学结局的预测因素。

结果

无RFA手术相关死亡,治疗的技术有效性为89.1%(123/138)。中位随访时间为30个月。LTP率为32.6%(45/138),中位OS为36个月。1年、3年和5年OS率分别为90.6%、45.6%和22.9%。单因素分析显示,肿瘤大小和消融边缘是影响LTPFS的因素,而肝外疾病(EHD)、肿瘤数量和肿瘤大小是影响OS的因素。多因素分析显示,肿瘤大小大于3 cm和消融边缘小于或等于5 mm是LTPFS较短的独立预测因素,而肿瘤数量大于1、大小大于3 cm和存在EHD是OS较短的独立预测因素。

结论

RFA是治疗CRLM的一种安全有效的方法。肿瘤大小和消融边缘是影响LTPFS的重要因素。肿瘤数量、肿瘤大小和EHD也是影响OS的关键因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db2e/7509997/0346f12da31d/WJGO-12-1044-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验